Dr. Hakim Djaballah is the president & CEO of Keren Therapeutics, a biotech company dedicated to the discovery of therapeutics to treat age-related disorders, such as sarcopenia. He is the former CEO of Institut Pasteur in South Korea, a translational institute focusing on infectious diseases & oncology. Prior to his move to South Korea, Dr. Djaballah was affiliated for 11 years with the Memorial Sloan Kettering Cancer Center in New York, USA; where he was the director of the high throughput drug screening laboratory. He received his BSc degree (Hon) in biochemistry with biotechnology from the University of Birmingham (England) and a doctorate degree in biochemistry from the University of Leicester (England). To date, Dr. Djaballah has published more than 96 peer-reviewed articles, book chapters, and reviews. He is an inventor on a number of patents and a founder of two Biotechnology Companies. He is the recipient of the 2007 Robots and Vision User Recognition Award, and an SLAS Fellow of the Society for Laboratory Automation and Screening. Dr. Djaballah is a key Thought Leader on drug discovery & development, sits on several scientific advisory boards, & a sought-after speaker.
Dr. Hakim Djaballah's research interests are drug discovery, drug development, functional genomics, infectious diseases, oncology, and public health. His present research focuses on understanding muscle function loss with aging and how to reverse it in the case of sarcopenia.